Search

everythinglearnresearchcommunity

for

Search:↓

A user shared their 4-month progress using oral Minoxidil (3mg) and Finasteride (1.1mg) with a 0.5mm derma roller twice a week, noting visible improvement. Others congratulated and encouraged them to continue the treatment.

The conversation discusses alternative and unorthodox hair loss treatments, including RU58841, nandrolone, and dianabol, as well as theoretical approaches involving high doses of estrogen and selective estrogen receptor modulators. These methods are considered extreme and potentially harmful but are explored for those unable to tolerate traditional 5-alpha reductase inhibitors.

KX-826 is being discussed for hair loss treatment, with users debating between 0.5% and 0.9% solutions and foam. Some report side effects like headaches, while others see no changes; it blocks androgen receptors without reducing DHT levels.

RU58841 is debated for hair regrowth, with some users reporting no benefits and potential side effects, while others claim success when combined with dutasteride. Many suggest safer, well-researched treatments like finasteride and minoxidil for hair loss management.

A 27-year-old male experienced significant hair regrowth using 0.5 mg Dutasteride and 2.5 mg Oral Minoxidil daily, with minimal side effects. He noticed improvement in hairline and crown after an initial shedding phase, and he did not use Finasteride prior to this treatment.

J. Hewitt plans to trial hair multiplication in Japan by the end of 2019. The technique was developed by German researchers at the University of Berlin and formed the company "TissUse."

A user shared a 3-month hair regrowth progress using minoxidil and microneedling. They also use rosemary oil and plan to continue treatment for at least 6-9 more months.

Pyrilutamide 0.9% (kx-826) is available for shipping to Europe from Amazon US and Koshinemall. Shipping costs and availability vary between the two shops.

The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.

GT20029 is a new hair loss treatment in Phase 3 trials in China, using PROTAC technology to target androgen receptors, potentially with fewer side effects than finasteride and minoxidil. VDPHL01, a second-generation minoxidil, is also mentioned as potentially more effective.